Hongtao Yu

Aug 25, 2024 | bpspubs.onlinelibrary.wiley.com | Muhammad Sadiq |Hongtao Yu |Magnus Åstrand |Ian Scott

What is already known about this subject Tozorakimab, a high-affinity human monoclonal antibody, neutralizes IL-33. In a phase 1 study in healthy adults and patients with chronic obstructive pulmonary disease, tozorakimab was well tolerated and demonstrated linear and time-independent pharmacokinetics (PK). Biomarker measurements of the IL-33/tozorakimab and IL-33/sST2 complexes demonstrated target engagement (TE) in systemic circulation.

Aug 19, 2024 | bpspubs.onlinelibrary.wiley.com | Hongtao Yu |Peter J. Greasley |Philip Ambery |Late-Stage Development

CKDCalbumin plasma albumin concentration CD collecting duct CKD chronic kidney disease CO cardiac output CVP central venous pressure ECE endothelin converting enzyme eGFR estimated glomerular filtration rate GFR glomerular filtration rate GPinjury glomerular injury signal IFV interstitial fluid volume Kalbumin glomerular albumin sieving coefficient Km, gp, siev glomerular injury signal that produces half the maximum rise in the sieving coefficient MAP mean arterial pressure N number of...

Apr 8, 2024 | nature.com | Xuping Xie |Hongtao Yu |Jing Huang |Pei-Yong Shi

AbstractDrug resistance poses a significant challenge in the development of effective therapies against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and M49K/S301P, in the 3C-like protease (3CLpro) that confer resistance to a novel non-covalent inhibitor, WU-04, which is currently in phase III clinical trials (NCT06197217).

Feb 9, 2023 | mdpi.com | Hongtao Yu

6. Experimental Results of New PE Teaching ModelIn order to verify the effect of the application model based on the Internet of Things and artificial intelligence in innovative physical education practice teaching in colleges and universities, this paper carried out verification under the Gold-SA and BPNN models.